Condition 1: drug abuse. Condition 2: Anxiety. Condition 3: depression. Condition 4: sexual dysfunction. Condition 5: Sleep disorder. Condition 6: Cognitive disorders. Opioid related disorders Anxiety disorder, unspecified Major depressive disorder, single episode, unspecified Unspecified sexual dysfunction not due to a substance or known physiological condition Sleep disorder, unspecified Mental and behavioural disorders due to use of opioids : residual and late-onset psychotic disorder
Conditions
Interventions
Intervention 1: Intervention group: recipients of rosemary capsules containing 500 mg of the effective ingredient of rosemary, every 12 hours for 4 weeks. Intervention 2: Control group: receiving a pl
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 60 years Proficiency in Persian language Literacy for reading and writing Methadone maintenance treatment
Exclusion criteria
Exclusion criteria: No history of heart disease No diabetes Absence of liver and kidney failure Absence of pregnancy Epilepsy and life-threatening diseases Lack of chronic treatment with antidepressants Not receiving antidepressants, benzodiazepines, melatonin and other sleep medications during the past month Not having moderate to severe mental disability No history of allergic reaction to rosemary and similar products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anxiety. Timepoint: Immediately before the beginning of the study and after the end of the intervention (fourth week). Method of measurement: Hospital Anxiety and Depression Scale (HADS).;Sexual disorders. Timepoint: Immediately before the beginning of the study and after the end of the intervention (fourth week). Method of measurement: changes in sexual functioning questionnaire (csfq-14).;Cognitive impairment. Timepoint: immediately before the beginning of the study and after the end of the intervention (fourth week). Method of measurement: Montreal Cognitive Assessment.;Sleep disorder. Timepoint: Immediately before the beginning of the study and after the end of the intervention (fourth week). Method of measurement: Pittsburgh Sleep Quality Index (PSQI).;Depression disorder. Timepoint: immediately before the beginning of the study and after the end of the intervention (fourth week). Method of measurement: Hospital Anxiety and Depression Scale (HADS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarziyeh Heidarzadeh
Kerman University of Medical Sciences
Outcome results
None listed